Monitor Mondays

340B Drug Discount Program: What Happens Next?

June 11, 2018 Chuck Buck | Ronald Hirsch, MD | Mary Inman, Esq. |David Glaser, Esq.| J. Paul Spencer | Maureen Testoni, Esq.
Monitor Mondays
340B Drug Discount Program: What Happens Next?
Show Notes

Not unexpected but widely feared among healthcare providers, regulations setting 340B ceiling prices and establishing civil monetary penalties for drug manufacturers that knowingly and intentionally exceed those limits were delayed for the fifth time, until 2019, by the Trump Administration in a final rule published on Tuesday, June 5 in the Federal Register.

As the dust settles, America’s rural hospitals are expected to be impacted the most by an apparent lack of government enforcement, as the savings they receive from their participation in the 340B program —savings that are intended to keep doors open and allow for the provision of care for low-income and rural patients—are crucial to their survival.

Reporting on this developing story during the next edition of Monitor Mondays will be Maureen Testoni, Interim President and Chief Executive Officer for 340B Health, a nonprofit organization of more than 1,300 hospitals and health systems participating in the federal 340B drug pricing program.

Other segments to be featured on the broadcast include:

  • Monday Rounds: Ronald Hirsch, MD, vice president of R1 Physician Advisory Services, will be making his Monday Rounds with another installment of his popular segment.

  • Special Assignment: Senior healthcare analyst Frank Cohen will return to the broadcast to continue his reporting of alleged bias he is uncovering in extrapolation audits. Cohen is expected to report on how a Zone Program Integrity Contractor (ZPIC) turned a $4,000 overpayment into a $3 million overpayment using extrapolation.

  • Monday Focus: Nationally recognized whistleblower attorney Mary A. Inman, partner at Constantine Cannon’s London office, will have an update on the major whistleblower case that is pitting Aetna against CVS for price spreading—this at a time when the two entities are trying to merge.

  • Risky Business: Healthcare attorney David Glaser, with Fredrikson & Byron, will report on another example of a potentially troublesome issue that could pose a risk to your facility.

  • Medicare Advantage Report: Monitor Mondays national correspondent J. Paul Spencer, a senior healthcare consultant for DoctorsManagement, will continue to report on the vexing issue of Medicare Advantage.

Monitor with us™